|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/20 Adaptimmune Therapeutics PLC 10-K 12/31/19 118:15M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.85M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 124K
3: EX-10.4 Material Contract HTML 468K
4: EX-10.5 Material Contract HTML 852K
5: EX-10.6 Material Contract HTML 61K
6: EX-23.1 Consent of Experts or Counsel HTML 34K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 41K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 41K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 34K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 34K
94: R1 Document and Entity Information HTML 93K
58: R2 Consolidated Balance Sheets HTML 110K
19: R3 Consolidated Balance Sheets (Parenthetical) HTML 48K
81: R4 Consolidated Statements of Operations HTML 73K
93: R5 Consolidated Statements of Operations HTML 33K
(Parenthetical)
57: R6 Consolidated Statements of Comprehensive Loss HTML 58K
18: R7 Consolidated Statements of Comprehensive Loss HTML 45K
(Parenthetical)
80: R8 Consolidated Statements of Changes in Equity HTML 88K
95: R9 Consolidated Statement of Change in Equity HTML 41K
(Parenthetical)
52: R10 Consolidated Statements of Cash Flows HTML 109K
39: R11 Consolidated Statements of Cash Flows HTML 36K
(Parenthetical)
75: R12 General HTML 37K
114: R13 Summary of Significant Accounting Policies HTML 290K
53: R14 Revenue HTML 67K
40: R15 Financial instruments HTML 102K
76: R16 Other current assets HTML 48K
115: R17 Property, plant and equipment, net HTML 53K
54: R18 Intangible assets, net HTML 47K
38: R19 Operating Leases HTML 68K
83: R20 Accrued expenses and other current liabilities HTML 53K
96: R21 Contingencies and commitments HTML 62K
55: R22 Stockholders' equity HTML 39K
16: R23 Share-based compensation HTML 235K
84: R24 Income taxes HTML 149K
97: R25 Geographic information HTML 48K
56: R26 Subsequent event HTML 36K
17: R27 Summary of Significant Accounting Policies HTML 350K
(Policies)
82: R28 Summary of Significant Accounting Policies HTML 226K
(Tables)
98: R29 Revenue (Tables) HTML 67K
118: R30 Financial instruments (Tables) HTML 96K
78: R31 Other current assets (Tables) HTML 48K
37: R32 Property, plant and equipment, net (Tables) HTML 53K
51: R33 Intangible assets, net (Tables) HTML 47K
117: R34 Operating Leases (Tables) HTML 69K
77: R35 Accrued expenses and other current liabilities HTML 49K
(Tables)
36: R36 Share-based compensation (Tables) HTML 191K
50: R37 Income taxes (Tables) HTML 151K
116: R38 Geographic information (Tables) HTML 47K
79: R39 General (Details) HTML 35K
101: R40 Summary of Significant Accounting Policies - Going HTML 74K
concern (Details)
87: R41 Summary of Significant Accounting Policies - HTML 35K
Foreign currency (Details)
27: R42 Summary of Significant Accounting Policies - HTML 36K
Accumulated other comprehensive income (Loss)
(Details)
67: R43 Summary of Significant Accounting Policies - Cash, HTML 44K
cash equivalents and restricted cash (Details)
100: R44 Summary of Significant Accounting Policies - HTML 115K
Available-for-sale debt securities (Details)
85: R45 Summary of Significant Accounting Policies - HTML 39K
Accounts receivable (Details)
26: R46 Summary of Significant Accounting Policies - HTML 42K
Property, plant and equipment (Details)
66: R47 Summary of Significant Accounting Policies - HTML 35K
Intangibles (Details)
99: R48 Summary of Significant Accounting Policies - HTML 34K
Leases (Details)
88: R49 Summary of Significant Accounting Policies - HTML 34K
Segment Reporting (Details)
69: R50 Summary of Significant Accounting Policies - HTML 40K
Revenue from contract with customers (Details)
106: R51 Summary of Significant Accounting Policies - HTML 36K
Research and Development Expenditure (Details)
48: R52 Summary of Significant Accounting Policies - HTML 34K
Retirement Benefits (Details)
34: R53 Summary of Significant Accounting Policies - Loss HTML 43K
per share (Details)
70: R54 Summary of Significant Accounting Policies - HTML 36K
Antidilutive Securities (Details)
107: R55 Summary of Significant Accounting Policies - HTML 39K
Options (Details)
49: R56 Summary of Significant Accounting Policies - New HTML 43K
accounting pronouncements (Details)
35: R57 Revenue (Details) HTML 37K
68: R58 Revenue - Revenue from contracts with customers HTML 39K
(Details)
108: R59 Revenue - Deferred revenue (Details) HTML 51K
60: R60 Financial instruments - Fair value of assets and HTML 57K
liabilities (Details)
22: R61 Financial instruments - Cash Equivalents and HTML 42K
Short-term Deposits (Details)
89: R62 Financial instruments - Collaboration and License HTML 44K
Agreement (Details)
102: R63 Financial instruments - Foreign Exchange Risk HTML 34K
(Details)
63: R64 Other current assets (Details) HTML 48K
25: R65 Property, plant and equipment, net - Schedule of HTML 53K
Property and Equipment (Details)
92: R66 Property, plant and equipment, net - Depreciation HTML 35K
Expense (Details)
105: R67 Intangible assets, net - Tabular Disclosure HTML 44K
(Details)
64: R68 Intangible assets, net - Amortization Expense HTML 35K
(Details)
21: R69 Intangible assets, net - Aggregate Amortization HTML 45K
Expense (Details)
31: R70 Operating Leases - Lease Cost (Details) HTML 47K
47: R71 Operating Leases - Maturities (Details) HTML 51K
112: R72 Accrued expenses and other current liabilities HTML 49K
(Details)
74: R73 Accrued expenses and other current liabilities - HTML 45K
Supply agreement (Details)
28: R74 Contingencies and commitments - Operating Leases HTML 48K
(Details)
44: R75 Contingencies and commitments - Capital HTML 37K
Commitments (Details)
109: R76 Contingencies and commitments - Clinical Trials HTML 49K
and Contract Manufacturing Commitments (Details)
71: R77 Contingencies and commitments - Collaborations and HTML 86K
License Agreements (Details)
33: R78 Stockholders' equity - Ordinary Shares (Details) HTML 42K
43: R79 Stockholders' equity - Underwritten public HTML 50K
offering and Registered direct offering (Details)
30: R80 Share-based compensation - Option Plans (Details) HTML 146K
46: R81 Share-based compensation - Share-based HTML 40K
Compensation Expense (Details)
111: R82 Share based compensation - Unrecognized HTML 37K
Compensation Cost (Details)
73: R83 Share-based compensation - Options (Details) HTML 43K
29: R84 Share based compensation - Option Activity HTML 91K
(Details)
45: R85 Share based compensation - Stock Options HTML 83K
Outstanding (Details)
110: R86 Share based compensation - Options Exercised HTML 44K
(Details)
72: R87 Share-based compensation - Fair Value Assumptions HTML 47K
(Details)
32: R88 Income taxes - Income before Income Taxes HTML 41K
(Details)
41: R89 Income taxes - Components of Income Tax Expense HTML 46K
(Benefit) (Details)
61: R90 Income taxes - Reconciliation of Deferred Tax HTML 67K
Assets and Liabilities (Details)
23: R91 Income taxes - Change in Valuation Allowance HTML 43K
(Details)
90: R92 Income taxes - Reconciliation of Effective Tax HTML 61K
Rate (Details)
103: R93 Income taxes - Tax Rates (Details) HTML 37K
62: R94 Income taxes - Change in Tax Rate (Details) HTML 60K
24: R95 Income taxes - Unrecognized Tax Benefits (Details) HTML 34K
91: R96 Geographic information - Operations by Geographic HTML 40K
Area - Long-lived Assets (Details)
104: R97 Geographic information - Major Customers (Details) HTML 41K
65: R98 Subsequent events (Details) HTML 49K
20: XML IDEA XML File -- Filing Summary XML 215K
59: XML XBRL Instance -- adap-20191231x10kb99908_htm XML 2.90M
86: EXCEL IDEA Workbook of Financial Reports XLSX 118K
12: EX-101.CAL XBRL Calculations -- adap-20191231_cal XML 202K
13: EX-101.DEF XBRL Definitions -- adap-20191231_def XML 694K
14: EX-101.LAB XBRL Labels -- adap-20191231_lab XML 1.63M
15: EX-101.PRE XBRL Presentations -- adap-20191231_pre XML 1.23M
11: EX-101.SCH XBRL Schema -- adap-20191231 XSD 239K
42: JSON XBRL Instance as JSON Data -- MetaLinks 407± 653K
113: ZIP XBRL Zipped Folder -- 0001558370-20-001571-xbrl Zip 665K
| adap_Ex32_1 |
Exhibit 32.1
Section 906 Certificate
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), I, Adrian Rawcliffe, Chief Executive Officer of Adaptimmune Therapeutics plc, a public limited company incorporated under English law (the “Company”), hereby certify, to my knowledge, that:
1.The Company’s annual report on Form 10-K for the year ended December 31, 2019, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 27, 2020
|
|
|
|
|
/s/ Adrian Rawcliffe |
|
|
|
|
|
Chief Executive Officer and Director |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/27/20 | 8-K | ||
| For Period end: | 12/31/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/06/24 Adaptimmune Therapeutics plc 10-K 12/31/23 131:16M Toppan Merrill Bridge/FA 4/18/23 Adaptimmune Therapeutics plc S-4/A 7:5.6M Toppan Merrill/FA 4/05/23 Adaptimmune Therapeutics plc S-4 7:4.5M Toppan Merrill/FA 3/06/23 Adaptimmune Therapeutics plc 10-K 12/31/22 117:15M Toppan Merrill Bridge/FA 3/14/22 Adaptimmune Therapeutics plc 10-K 12/31/21 109:13M Toppan Merrill Bridge/FA 2/25/21 Adaptimmune Therapeutics plc 10-K 12/31/20 112:13M Toppan Merrill Bridge/FA 8/10/20 Adaptimmune Therapeutics plc S-3ASR 8/10/20 5:1.6M Toppan Merrill/FA |